Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently completed kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, a critical step toward future formulation development, GMP production, and clinical studies.
To support its pipeline, Onco-Innovations has signed a letter of intent with Nanosoft Polymers to advance polymer development, drug delivery optimization, and formulation work. Additionally, engagements with Nucro-Technics and Avance Clinical are supporting bioanalytical development and clinical and regulatory planning. These efforts reflect the company’s broader strategy to build the manufacturing, formulation, and clinical infrastructure needed to advance ONC010 toward future first-in-human studies.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit the company’s website at https://oncoinnovations.com/.
The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
